Our mission is

to contribute to well-being of humanity by treating chronic immune diseases through peptide drugs we discover and develop.

Thank you for visiting our website.

KINE SCIENCES is a company that develops ultra-small peptide innovative medicines based on functional immunomics.

We discovered the function of a novel cytokine ERDR1 for the first time in the world and since we have been developing drug candidates of ultra-small peptide with private and public funding including the one from Korea Drug Development Fund for consecutive four years.

The diseases we aim to treat are chronic immune diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, psoriasis, cancer, Alzheimer’s disease, and many rare immune diseases.

Though we live in an era when we see more research on life sciences and more drugs on the market than any other era of human history, we humans have yet to find cures for these chronic immune diseases by seeing occurrence of resistance or relapse which make lifelong treatment of expensive medicines inevitable for patients.

These diseases put a great burden not only on patients themselves but their families and the society as a whole.

KINE SCIENCES is committed to treating chronic immune diseases, making lives of patients and their families better, and ultimately improving well-being of humanity by developing safer, more economical and more convenient medicines of ultra small peptides.

Please give us encouragement and support for our daunting journey.


  • CTO Dae Ho Cho

  • Ph.D., Chicago Medical School; B.S., SUNY

    Professor of Convergence Research Institute, Korea University

    Head of Nano Bio Material Research Center, Korea University

    Professor of Department of Life Sciences, Sookmyung Women's University


Hee Kyung Kim

MBA, Sogang University; B.S. Pharmacy, Seoul National University

SVP, Clinical Science Division & RA, Samsung Bioepis

VP, Strategic Business Development, Samsung Electronics

Head of Market Access Division & Compliance, Novartis Korea

Youn Been Kim

BPharm, Sookmyung Women’s University

MBA, Yonsei University

Marketing Director, Infectious Diseases, Transplantation & Immunology, Novartis Korea

Head of Global Partnership and Research Ops, Novartis Institute for Tropical Diseases Singapore

CEO, Research Investment for Global Health Technology Fund Foundation

Dae Seok Shim

B.A. Business Administration, Hongik University

Director of Anjin Deloitte

CPA of Citi Bank

Head of Business
Sun Young Park

Ph.D., Cell Biology, Sookmyung Women's University

Senior Researcher, Sookmyung Women's University

Senior Researcher, SIS Immunology Research Center, Sookmyung Women's University

Research Professor, Sookmyung Women’s University

Head of Project
/Process Management
A Yeon Cho

Ph.D., College of Medicine, Seoul National University; B.S. Biological Sciences, KAIST

Chief Researcher, Strategic Business Development Lead, CHABiotech

Principal Engineer, Corporate Management and Business Development, Samsung Bioepis

Senior Engineer, Samsung Advanced Institute of Technology, Samsung Electronics


  • 03
    CEOs of Hee Kyung Kim & Dae Ho Cho inaugurated
    KINE-101B GLP study initiated


  • 12
    Move the head office to PNM Tower
    KINE-101A Phase 1 IND approved by US FDA
    Substance patents regarding KINE-101, KINE-201 and KINE-301 registered in US


  • 07
    Project awarded by Korea Patent Strategy Development Institute


  • 03
    Change of corporate name to KINE SCIENCES Co.,Ltd.
    R&D Center of KINE SCIENCES established
    KINE-101A GLP study initiated
    Corporate R&D Center certification acquisition


  • 10
    Established joint research institute with Korea University
    Certified by Korea Government as a Venture Company


  • 12
    Patents regarding KINE-101, KINE-201 and KINE-301 filed in major foreign conturies


  • 08
    Company founded(Bio Pep Co., Ltd.)
    Selected as a new drug development project by the Ministry of New Drug Development Project
Contributing to better lives of mankind
by developing innovative therapies
Vision 2025
Growing as a unicorn company
carrying out more than five global clinical trials with new molecules

Core Value

    Pursuing the best through change and innovation
    Being flexible and adaptable to ever-changing environment
    Sticking to the principle and being honest
    Being committed to common goal and vision
    Moving forward hand in hand
Continuous InnovationRaises Hope for Humanity.